12th week of 2014 patent applcation highlights part 52 |
Patent application number | Title | Published |
20140080745 | SURFACTANT COMPOSITIONS AND USE FOR AQUEOUS COMPOSITIONS - A surfactant composition selected from the group consisting of; (R | 2014-03-20 |
20140080746 | CLEANSING COMPOSITION FOR SKIN OR HAIR - Provided is a cleansing composition for skin or hair which can provide a good rinse feel and can enhance the combing property of hair after rinsing and the manageability after drying in application to the hair and can impart a sufficient moist feeling to skin in application to the skin. | 2014-03-20 |
20140080747 | SKIN CLEANSING COMPOSITION - The present invention provides a skin cleansing composition comprising the following components (A), (B), and (C):
| 2014-03-20 |
20140080748 | EASY RINSE DETERGENT COMPOSITIONS COMPRISING ISOPRENOID-BASED SURFACTANTS - The present invention relates to detergent compositions containing a specific blend of isoprenoid-based surfactants to deliver easy-rinse (low sudsing) cleaning performance. | 2014-03-20 |
20140080749 | FABRIC CARE COMPOSITION - An aqueous fabric care composition having perfume micro-capsules. The smell provided by the freshly formulated composition and the same composition after storage has a limited character and intensity change. The composition has from about 0 wt % to about 5 wt % of anionic surfactant, from about 0 wt % to about 3 wt % of cationic surfactant, from about 0 wt % to about 3 wt % of a non-ionic surfactant, from about 0.01 wt % to about 15 wt % of perfume micro-capsules and water. | 2014-03-20 |
20140080750 | PROCESS TO INTRODUCE HYDROPHOBIC ANTIBACTERIAL COMPOUND IN AN AQUEOUS COMPOSITION - Process to prepare an aqueous composition comprising a non-ionic antibacterial compound having a ClogP above about 2, the process having the steps of:
| 2014-03-20 |
20140080751 | INTERNAL OLEFINIC SULFONATE COMPOSITION AND CLEANSING COMPOSITION CONTAINING THE SAME - Provided is an internal olefin sulfonate composition which is capable of exerting good foamability at the same time with foam quality, foam dissipation property, and less irritation to the skin at high levels, and a cleansing composition containing the same. | 2014-03-20 |
20140080752 | White Carbon Black Formulations and Methods - Compositions, method, and devices are provided for cleaning surfaces, including glass and plastic surfaces. The compositions include white carbon black. The white carbon black can be combined with a binder to form a white carbon black formulation. The white carbon black formulation can be used to clean various glass and plastic surfaces, including transparent surfaces. | 2014-03-20 |
20140080753 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 2014-03-20 |
20140080754 | DIAGNOSTIC METHOD FOR BACTERIAL MENINGITIS - It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis. | 2014-03-20 |
20140080755 | SELECTING AND STABILIZING dsRNA CONSTRUCTS - The invention provides methods for selecting nucleotide sequences that yield dsRNA-mediated gene suppression in a target organism and enable their uptake by the target organism. The invention further provides expression constructs that confer stabilized expression of such sequences in a transgenic host cell, and methods for their use. Also provided are organisms, cells and tissues prepared by a method of the invention. | 2014-03-20 |
20140080756 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES - The present invention provides a compound of Formula (I) | 2014-03-20 |
20140080757 | GLUCAGON ANALOGUES - The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2014-03-20 |
20140080758 | TREATMENT OF KIDNEY DISORDERS WITH VIP FRAGMENTS - The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of kidney disease, in particular kidney fibrosis, and other associated conditions. | 2014-03-20 |
20140080759 | COMPOSITIONS COMPRISING MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN AND GLYCOSAMINOGLYCANS - The present invention relates to a composition comprising a Nucant multivalent synthetic compound and a glycosaminoglycan, the admixture of both compounds forming microspheres comprising both compounds, as well as their use for the treatment or prevention of diseases associated with deregulation of proliferation and/or angiogenesis, such as cancer, inflammatory disease, or for promoting wound healing. | 2014-03-20 |
20140080760 | COMBINATION THERAPY FOR TREATMENT OF CANCER - The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent. | 2014-03-20 |
20140080761 | PROTEOGLYCAN-CONTAINING MATERIAL - The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like. | 2014-03-20 |
20140080762 | HYD1 PEPTIDES FOR RELAPSED CANCER - The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as α4 integrin and CD44 expression. | 2014-03-20 |
20140080763 | N-CARBOXYALKYLAURISTATINS AND USE THEREOF - The present application relates to new derivatives, substituted on the N terminus by a carboxyalkyl group, of monomethylauristatin E and monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and to the use of these derivatives for producing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments may be applied as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 2014-03-20 |
20140080764 | Drug Containing Recombinant Mistletoe Lectins for Treating Malignant Melanoma - The invention relates to a drug and/or pharmaceutical composition for treating metastatic tumors, in particular of malignant melanoma, above all of stage IV malignant melanoma, and to the use of said drug, in particular the use of said drug in select patient populations. | 2014-03-20 |
20140080765 | NOVEL METALLOPROTEIN AND PROCESS FOR PRODUCING SAME, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL AND CONJUNCTIVAL DISEASES COMPRISING SAID METALLOPROTEIN - The present invention provides: a novel metalloprotein, i.e., selenium-lactoferrin; and a process for producing the metalloprotein. Selenium-lactoferrin according to the present invention can be produced suitably by adding a selenium salt to a solution containing lactoferrin and/or apolactoferrin and then subjecting the resultant mixed solution to dialysis or ultrafiltration. | 2014-03-20 |
20140080766 | COMPOSITIONS AND METHODS FOR MACROMOLECULAR DRUG DELIVERY - The present invention features compositions and methods for delivering a therapeutic agent to the cytoplasm of a cell. We have developed, inter alia, a system in which two or more distinct moieties—at least one therapeutic moiety and at least one potentiating moiety—selectively target and specifically bind cell surface molecules that are then internalized to an intracellular, membrane-bound compartment, such as an endosome. In some embodiments, as discussed further below, a third moiety that induces clustering of the targeted cell surface molecule can also be employed. Regardless of whether the compositions and methods include two or three moieties, the therapeutic agent can be any agent one wishes to deliver to the cytoplasm of a cell, and the potentiating agent can be any agent that destabilizes the intracellular, sub-cellular compartment in which the therapeutic agent is sequestered. The potentiating moiety can include, for example, a lytic agent (i.e., an agent that lyses or otherwise increases the permeability of the membrane of the intracellular compartment containing the therapeutic agent). To direct the various moieties of the system, including the therapeutic, potentiating, and clustering moieties, to a selected cellular target, any of the moieties can include a binding agent that selectively targets and specifically binds a molecule present on the surface of the targeted cell. | 2014-03-20 |
20140080767 | MATERNAL SIALIC ACID SUPPLEMENTATION - The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements. | 2014-03-20 |
20140080768 | PRODRUGS OF DHODH INHIBITORS AND THEIR USES - The invention generally relates to Pro-Drugs of dihydroorotate dehydrogenase (DHODH) inhibitors and methods of use thereof. In certain embodiments, the invention provides a DHODH inhibitor compound including a cleavable functional group that increases bioavailability as compared to a form of the DHODH inhibitor without the functional group, rendering the former more suitable for therapeutic use. | 2014-03-20 |
20140080769 | SUBSTRATE REDUCTION THERAPY - The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. | 2014-03-20 |
20140080770 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME - An arylalkylamine compound is represented by the following formula [I-e] or a pharmaceutically acceptable salt thereof. | 2014-03-20 |
20140080771 | METHOD FOR TREATING RHINITIS AND SINUSITIS BY RHAMNOLIPIDS - The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant. | 2014-03-20 |
20140080772 | TREATMENTS FOR MELANOMA - The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides. | 2014-03-20 |
20140080773 | Composition for Delivering an Anti-Ageing Effect on the Skin and a Method for Improving Skin Characteristics - A composition suitable to improve skin characteristics is described along with a regimen to improve skin characteristics. The composition is not limited to format, and can be in the form of a capsule, tablet or food product. When consumed within a defined regimen, the composition with active mixture results in skin that is smoother and with a reduction in wrinkles. | 2014-03-20 |
20140080774 | IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS - The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier. | 2014-03-20 |
20140080775 | MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 2014-03-20 |
20140080776 | COMPOSITION AND METHODS FOR EXTRACTING AND USING PHYTOCHEMICALS FOR THE TREATMENT OF INFLUENZA - Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition is produced by a process comprising providing one or more pomegranate solids selected from the group consisting of a pericarp, inner membrane and seeds, creating a mixture comprising said one or more pomegranate solids in an aqueous solution, heating said mixture to a temperature that permits enzyme catalysis of said pomegranate solids, and removing residual insoluble solid materials from said mixture to provide said pomegranate extract. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements. | 2014-03-20 |
20140080777 | SPINOSYN-PRODUCING POLYKETIDE SYNTHASES - The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in | 2014-03-20 |
20140080778 | USE OF SECNIDAZOLE IN TREATMENT OF DENTAL INFECTIONS - The invention relates to the combination of secnidazole with an antibiotic of the macrolide family, preferably azithromycin 11, for oral treatment of dental infections, which enables a considerable reduction in the length of treatment and the doses administered in comparison with the conventional treatment. | 2014-03-20 |
20140080779 | MACROCYCLIC LACTONES AND USE THEREOF - The present invention is directed to the use of macrocyclic lactones, in particular avermectins, in the treatment of conditions whose formation, occurrence, development or growth is associated with aberrant Wnt signalling in particular the treatment of colorectal cancer. | 2014-03-20 |
20140080780 | identification of compounds that disperse tdp-43 inclusions - Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described. | 2014-03-20 |
20140080781 | Composition of HMB and ATP and Methods of Use - The present invention provides a composition comprising HMB and ATP. Methods of administering HMB and ATP to an animal are also described. HMB and ATP are administered to increase power and strength. The combination of HMB and ATP together has a synergistic effect, which results in a surprising and unexpected level of improvement in power and strength. HMB and ATP are also administered to increase lean body mass and muscle hypertrophy and to prevent typical declines in performance that are characteristic of overreaching. | 2014-03-20 |
20140080782 | METHODS OF DIAGNOSING AND TREATING PANCREATIC CANCER - A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer. | 2014-03-20 |
20140080783 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS - The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide with other compounds, to patients suffering from cancer are described. | 2014-03-20 |
20140080784 | USE OF URIDINE AND DEOXYURIDINE TO TREAT FOLATE-RESPONSIVE PATHOLOGIES - The present invention relates to a pharmaceutical or dietary composition comprising deoxyuridine and a pharmaceutically or dietetically suitable carrier. Another aspect of the present invention relates to a method of supplementing the dietary needs of a subject. This method includes administering to the subject a dietary supplementing effective amount of deoxyuridine. Yet another aspect of the present invention relates to a method of treating cancer in a subject. This method includes selecting a subject having cancer and administering to the selected subject a therapeutically effective amount of uridine, thereby treating the cancer in the selected subject. | 2014-03-20 |
20140080785 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK - Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject. | 2014-03-20 |
20140080786 | MEDICAL AND NUTRITIONAL APPLICATIONS OF HIGHLY REFINED CELLULOSE - The present invention provides a method for using processed-cellulose. Preferably, the processed cellulose is a highly refined cellulose (HRC). The HRC is useful in a number of medical and nutritional applications. These medical and nutritional applications can include, but are not limited to, administering effective amounts of the HRC for lowering values of risk factor measurements for such diseases as arteriosclerotic cardiovascular disease and diabetes. Treatment of other diseases and conditions with the HRC is also possible. | 2014-03-20 |
20140080787 | Method for the Treatment of Neuropathies Associated with Charcot-Marie-Tooth 1A (CMT1A) Disease - The present invention relates to compositions and methods for the treatment, prevention, and diagnosis of neuropathies due to PMP22 mis-expression in a subject having Charcot-Marie-Tooth disease, especially Charcot-Marie-Tooth 1A disease. The present invention incorporates the use of small molecule proteasome inhibitors such as, but not limited to, Bortezomib to inhibit or reduce the overexpression of the PMP2 gene. | 2014-03-20 |
20140080788 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS - Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R | 2014-03-20 |
20140080789 | Method of Treating Diabetes, Glucose Intolerance, Insulin Resistance and/or Diabetes-Induced Diastolic Dysfunction - A method of treating, reversing, or ameliorating type 2 diabetes (DM) includes administering to a host in need thereof a therapeutically effective amount of a mitochondria-targeted antioxidant, such as mito-TEMPO (2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride). | 2014-03-20 |
20140080790 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE - Compounds represented by formula (I): | 2014-03-20 |
20140080791 | OMEGA-3 PHOSPHOLIPID SUPPLEMENTS FOR FEMALES - The invention relates to omega-3 phospholipid supplements for females, and in particular to omega-3 phospholipid supplements with increased bioavailability as evidenced by increased EPA and DHA in plasma phospholipids and an increase in omega-3 index as compared to males. In preferred embodiments, the omega-3 phospholipid is krill oil. | 2014-03-20 |
20140080792 | Treatment method for a hydrocarbon-containing system using a biocide - A method for reducing the effects of biological contamination in a hydrocarbon-containing system comprising the steps of continuously adding a formulation comprising tris(hydroxymethyl)phosphine or a tetrakis(hydroxymethyl)phosphonium salt to the system for one day or more; monitoring the efficacy of the continuous treatment by an assessment of the extent to which there is any effect on the environment that is attributable to metabolic activity of active microbes present in the system; wherein the tris(hydroxymethyl)phosphine or tetrakis(hydroxymethyl)phosphonium salt is added at a concentration of from 1 to 30 ppm based on the total volume of aqueous fluid added to the system, and wherein the formulation is added to the system at a stage to minimize incompatibility with any other chemicals that are added to the aqueous fluid. The treatment disrupts the microbial activity of active microbes in the hydrocarbon-containing system and can prevent or reduce detrimental effects arising from the presence of active microbes in the system. | 2014-03-20 |
20140080793 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS - The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP). | 2014-03-20 |
20140080794 | Methods and Compositions for the Treatment of Estrogen-Dependent Hyperproliferative Uterine Disorders - The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects. | 2014-03-20 |
20140080795 | NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction - Methods for the treatment or prevention of diseases which are caused by the decreased concentrations of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by the methods of the invention include chronic obstructive pulmonary disease (COPD) and asthma, including steroid resistant COPD and asthma. The invention provides methods for treating or preventing of diseases caused by the degradation of HDAC2 by providing to the subject in need of treatment or prevention a molecular compound capable of preventing the degradation of HDAC2. Such molecular compounds include Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators. Methods are further provided for the treatment and prevention of COPD and asthma by providing to a subject in need of such treatment and prevention a nucleic acid which causes expression of HDAC2 in lung cells and/or a nucleic acid which causes expression of Nrf2 in lung cells. | 2014-03-20 |
20140080796 | ACETYLTANSHINONE IIA (ATA) AS ANTICANCER AGENT - The present invention relates to the use of a compound of Formula I for the manufacture of a medicament for treating or preventing cancer in a subject. Formula I | 2014-03-20 |
20140080797 | SUBSTITUTED PORPHYRINS - Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described. | 2014-03-20 |
20140080798 | VEGFR3 INHIBITORS - This invention relates to compounds of the formula (I): | 2014-03-20 |
20140080799 | Aminopyrimidine Kinase Inhibitors - Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. | 2014-03-20 |
20140080800 | Inhibitors of Histone Deacetylase - The present invention relates to compounds of formula (I): | 2014-03-20 |
20140080801 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE - Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2014-03-20 |
20140080802 | Inhibitors of Histone Deacetylase - The present invention relates to compounds of formula (I): | 2014-03-20 |
20140080803 | NOVEL TRPV3 MODULATORS - Disclosed herein are modulators of TRPV3 of Formula (I) | 2014-03-20 |
20140080804 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS - The invention provides novel substituted 6-arylamino pyridone carboxamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans. | 2014-03-20 |
20140080805 | PYRROLIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 2014-03-20 |
20140080806 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS - The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors. | 2014-03-20 |
20140080807 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS - The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them. | 2014-03-20 |
20140080808 | TETRAHYDROTHIAZEPINE DERIVATIVE - The present invention relates to a compound represented by the following general formula (I) | 2014-03-20 |
20140080809 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors - This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders. | 2014-03-20 |
20140080810 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula I: (I) and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens. | 2014-03-20 |
20140080811 | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non-Selective CA++ Activated ATP-Sensitive Cation Channels Regulatd by SUR1 Channels - NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose. | 2014-03-20 |
20140080812 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 2014-03-20 |
20140080813 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES - The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT | 2014-03-20 |
20140080814 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES - The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT | 2014-03-20 |
20140080815 | DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM) - The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 10 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg. | 2014-03-20 |
20140080816 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES - The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT | 2014-03-20 |
20140080817 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a compound represented by the formula (I): | 2014-03-20 |
20140080818 | TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN - The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimens. | 2014-03-20 |
20140080819 | HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS - The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes. | 2014-03-20 |
20140080820 | FUNGICIDAL AGENT COMBINATIONS - The invention relates to novel fungicidally active compound combinations of 2′-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula | 2014-03-20 |
20140080821 | PYRIMIDO-PYRROLO-OXAZINE-DIONE COMPOUND INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR - Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease. | 2014-03-20 |
20140080822 | Tricyclic Pyrazole Sulphonamide Compounds and Methods of Making and Using Same - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2014-03-20 |
20140080823 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; R | 2014-03-20 |
20140080824 | STRUCTURE-GUIDED IDENTIFICATION OF BINDING INTERACTIONS OF HUMAN LAMININ RECEPTOR PRECURSOR WITH LAMININ AND IDENTIFICATION OF COMPOUNDS THAT AFFECT BINDING - The present invention pertains to compounds which interfere with the binding of laminin to the laminin receptor (LamR). Such compounds are useful for treating diseases such as cancer, Alzheimer's Disease, and certain viral and bacterial infections. | 2014-03-20 |
20140080825 | Modulators of ATP-binding cassette transporters - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2014-03-20 |
20140080826 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2014-03-20 |
20140080827 | NOVEL KINASE MODULATORS - The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 2014-03-20 |
20140080828 | IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO - This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising 2-((benzo[d]imidazol-2-yl)thio)-N-phenylpropanamide derivatives, N-phenyl-2-((1-phenyl-benzo[d]imidazol-2-yl)thio)propanamide derivatives, or 2-((benzo[d]imidazol-2-yl)thio)-N-(2-chloro-4-methylphenyl)propanamide derivatives. The derivatives may be substituted with one or more substituents. Typically, the pharmaceutical composition comprises a compound of Formula (I), or salt, prodrug, or ester thereof wherein X, Y, and R1 to R7 are described herein. | 2014-03-20 |
20140080829 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. | 2014-03-20 |
20140080830 | Novel Compounds - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): | 2014-03-20 |
20140080831 | COMPOUNDS USEFUL FOR TREATING CANCER - A method of preventing, inhibiting, or treating cancer that includes contacting a cell with at least one compound of formula (Ia) or a pharmaceutically acceptable salt thereof: | 2014-03-20 |
20140080832 | IRE-1alpha INHIBITORS - Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies. | 2014-03-20 |
20140080833 | INTRACELLULAR KINASE INHIBITORS - Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs. | 2014-03-20 |
20140080834 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN - This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed. | 2014-03-20 |
20140080835 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2014-03-20 |
20140080836 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 2014-03-20 |
20140080837 | Sanglifehrin Derivatives and Methods for Their Production - There are provided inter alia compounds of formula (I) and (II) | 2014-03-20 |
20140080838 | Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes - The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB. | 2014-03-20 |
20140080839 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES - The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer. | 2014-03-20 |
20140080840 | Thiazolamine Derivative and Use Thereof as Anti-Picornaviral Infection Medicament - Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound. | 2014-03-20 |
20140080841 | Chemical Permeation Enhancers Enhance Nerve Blockade by Toxins - Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency. Thus, CPEs can provide marked prolongation of nerve blockade from TTX, without apparent local tissue toxicity, and therefore enhance the clinical applicability of TTX for prolonged-duration local anesthesia. | 2014-03-20 |
20140080842 | SMALL MOLECULE INHIBITORS OF TRPA1 - The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product. | 2014-03-20 |
20140080843 | METHODS FOR INHIBITING FASCIN - Provided are compositions and methods for treating a condition or disorder mediated by fascin activity in a subject in need thereof which method comprises administering to the subject a therapeutically effective amount of at least one compound of any one of Formula I-a to I-n, II, II-a, II-b or III or a pharmaceutically acceptable salt thereof. | 2014-03-20 |
20140080844 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase. | 2014-03-20 |